PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

MALVERN, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that Mr. Gary C. Evans, Chairman and Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Monday, November 7, 2005.

    WHEN:  Monday, November 7, 2005 1:00 p.m. (EST)

    WHERE: The Palace Hotel, 455 Madison Avenue, New York, NY

    HOW:   The live broadcast of the presentation can be accessed through our
           website at http://www.novavax.com. After the presentation date, the
           web cast will be archived on our website for 90 days.

About Novavax, Inc.

Novavax, Inc. is a product development company focused on the research, development and commercialization of products utilizing its proprietary drug delivery and biological technologies for large and growing markets. Novavax's drug delivery technologies include the micellar nanoparticle (MNP) technology which is the basis for the development of its first FDA-approved product, ESTRASORB(R). In addition to MNP, Novavax drug delivery technologies include Novasomes(R) (paucillamellar non-phospholipid liposomes) and Sterisomes(R) (subcutaneous depot injection) technologies. Novavax's vaccine technologies include its virus like particle (VLP) manufacturing technology utilizing the baculovirus expression system in insect cells as well as novel vaccine adjuvants based on Novasomes and dendrimer technologies.

SOURCE Novavax, Inc.
CONTACT: Investor Relations - Kathy Hamilton of Novavax, Inc., +1-484-913-1213,
khamilton@novavax.com